porfiromycin
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 1992 (NCT00002507)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@H]1[C@@H]2N1C- Mol. weight
- 348.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL521078 ↗
Also known as
- porfiromycin
- porfiromycin
- porfiromycin
- u-14743
- u-14743
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02183246 | Phase 3 | May 1, 2000 | Boehringer Ingelheim |
| NCT02209701 | Phase 1 | Dec 1, 1999 | Boehringer Ingelheim |
| NCT00003328 | Phase 3 | Dec 1, 1997 | Boehringer Ingelheim |
| NCT00002507 | Phase 3 | Nov 1, 1992 | Yale University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 2 | 1997 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 1992 |
2 organizations
Page 1 / 1